Anti-CD3 x Anti-PSCA Bispecific Antibody (IgG-IgG) (BSIG-H275)

Anti-CD3 x Anti-PSCA Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CD3 and anti-PSCA parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can retarget T cells to tumor cells. It is designed for the research of Prostate cancer therapy.

Datasheet

Specifications

Targets

CD3 & PSCA

Type

IgG-IgG

Species Reactivity

Human

Target 1

CD3

Host Animal 1

Human

Target 2

PSCA

Host Animal 2

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Prostate cancer

Targets

Target 1

CD3

Gene ID

916

UniProt ID

P07766

Alternative Names

CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3

Target 2

PSCA

Gene ID

8000

UniProt ID

D3DWI6

Alternative Names

PSCA; prostate stem cell antigen; PRO232

Welcome! For price inquiries, we will get back to you as soon as possible.

To order, please email

INQUIRY

Online Inquiry

45-1 Ramsey Road, Shirley, NY 11967, USA
Email:
Fax: 1-631-207-8356
Or Call
Tel: 1-631-381-2994